Browsing by Title

Now showing items 3406-3408 of 3408

Zanubrutinib for the treatment of MYD88 wild-type Waldenström macroglobulinemia: a substudy of the phase 3 ASPEN trial.

Dimopoulos, Meletios; Sanz, Ramon Garcia; Lee, Hui-Peng; Trneny, Marek; Varettoni, Marzia; Opat, Stephen; D'Sa, Shirley; Owen, Roger G.; Cull, Gavin; Mulligan, Stephen; Czyz, Jaroslaw; Castillo, Jorge J.; Motta, Marina; Siddiqi, Tanya; Gironella Mesa, Mercedes; Granell Gorrochategui, Miquel; Talaulikar, Dipti; Zinzani, Pier Luigi; Askari, Elham; Grosicki, Sebastian; Oriol, Albert; Rule, Simon; Kloczko, Janusz; Tedeschi, Alessandra; Buske, Christian; Leblond, Veronique; Trotman, Judith; Chan, Wai Y.; Michel, Jan; Schneider, Jingjing; Tan, Ziwen; Cohen, Aileen; Huang, Jane; Tam, Constantine S. (American Society of Hematology, 2020-12-08)

Patients with Waldenström macroglobulinemia (WM) lacking activating mutations in the MYD88 gene (MYD88WT) have demonstrated relatively poor outcomes to ibrutinib monotherapy, with no major responses reported in a phase 2 ...
Zinc Transporter 8 Autoantibodies (ZnT8A) and a Type 1 Diabetes Genetic Risk Score Can Exclude Individuals With Type 1 Diabetes From Inappropriate Genetic Testing for Monogenic Diabetes.

Hattersley, Andrew T.; McDonald, Timothy J. (American Diabetes Association, 2018-11-08)
Zinc transporter 8 autoantibody testing requires age-related cut-offs

Grace, S. L.; Cooper, A.; Jones, A. G.; McDonald, T. J. (BMJ, 2021-08-01)

INTRODUCTION: Zinc transporter 8 autoantibodies (ZnT8A) are biomarkers of beta cell autoimmunity in type 1 diabetes that have become more widely available to clinicians in recent years. Robust control population-defined ...

Browsing by Title

Zanubrutinib for the treatment of MYD88 wild-type Waldenström macroglobulinemia: a substudy of the phase 3 ASPEN trial. ﻿

Zinc Transporter 8 Autoantibodies (ZnT8A) and a Type 1 Diabetes Genetic Risk Score Can Exclude Individuals With Type 1 Diabetes From Inappropriate Genetic Testing for Monogenic Diabetes. ﻿

Zinc transporter 8 autoantibody testing requires age-related cut-offs ﻿

Zanubrutinib for the treatment of MYD88 wild-type Waldenström macroglobulinemia: a substudy of the phase 3 ASPEN trial.

Zinc Transporter 8 Autoantibodies (ZnT8A) and a Type 1 Diabetes Genetic Risk Score Can Exclude Individuals With Type 1 Diabetes From Inappropriate Genetic Testing for Monogenic Diabetes.

Zinc transporter 8 autoantibody testing requires age-related cut-offs